Peer-reviewed veterinary case report
Granulocyte-colony stimulating factor trial for dilated
By Park, Chul et al.·Published in The Journal of veterinary medical science·2007·Department of Veterinary Internal Medicine, South Korea·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Therapeutic trial of granulocyte-colony stimulating factor for dilated cardiomyopathy in three dogs.
- Species:
- dog
Plain-English summary
Three dogs with heart problems were brought in for evaluation and diagnosed with dilated cardiomyopathy (DCM), a condition that affects the heart's ability to pump blood. They were experiencing severe heart rhythm issues and their heart function was not improving with standard medications. The veterinarians then tried a new treatment using granulocyte-colony stimulating factor (G-CSF), which helped improve the dogs' heart function significantly without any side effects. This suggests that G-CSF could be a helpful option for dogs with DCM that don't respond to traditional treatments.
People also search for: dog heart problems treatment · dilated cardiomyopathy in dogs · G-CSF for dog heart disease
Abstract
Three dogs were presented to us for evaluation of cardiac problems. Electrocardiographic recordings revealed severe tachyarrhythmia and atrial fibrillation with ventricular tachycardia in 2 of the 3 dogs. The echocardiographic findings of the 3 dogs revealed markedly decreased fractional shortening and a marked increase in E-point septal separation. Based on the results of electrocardiographic and echocardiographic evaluation, the 3 dogs were diagnosed as dilated cardiomyopathy (DCM). The dogs were treated with conventional cardiac medication, but cardiac function did not improve and the clinical signs remained. We subsequently attempted treatment with granulocyte-colony stimulating factor (G-CSF; 10 microg/kg, subcutaneously). The specific purpose of G-CSF therapy for DCM was to improve cardiac function and a significant improvement in cardiac function was confirmed. The three dogs had no treatment side effects. This case report suggests that G-CSF might have therapeutic effects for medically refractory DCM in dogs.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/17917381/